Tranexamic Acid vs Hydroquinone for Melasma: A Complete Comparison

Tranexamic acid and hydroquinone are both used for melasma but act at different points: hydroquinone inhibits tyrosinase to reduce melanin production directly, while tranexamic acid interferes with the plasmin pathway that drives melanocyte stimulation and vascular activity in melasma.

Most comparisons online treat these as interchangeable "melasma treatments" and rank them by anecdote. They are not interchangeable. They differ in mechanism, in route of administration, in the safety questions a physician must screen for, and in how long they can reasonably be used. This guide sets out how each works, what the published evidence supports and where it is limited, how they are commonly combined in Korean dermatology practice, and what to ask before starting either. Both are prescription-controlled in most jurisdictions and neither should be self-directed.

What Melasma Is, and Why Single-Agent Thinking Fails

Melasma is a chronic, relapsing pigmentary disorder characterised by symmetrical patches, most often on the cheeks, forehead, and upper lip. It is not simply "excess melanin." Current understanding describes contributions from ultraviolet and visible light exposure, hormonal influences, dermal vascular changes, and basement-membrane disruption — which is why treatment aimed only at the melanocyte often produces partial or temporary improvement.

This matters for expectation-setting. Both agents discussed here are generally described in the literature as controlling rather than curing melasma, with recurrence common after discontinuation, particularly without strict photoprotection.

How Hydroquinone Works

Hydroquinone competitively inhibits tyrosinase, the rate-limiting enzyme in melanin synthesis, and has additional effects on melanocyte function. It is applied topically and has the longest track record of any depigmenting agent, having served for decades as the reference comparator in clinical trials.

Its recognised limitations are as important as its efficacy. Prolonged uninterrupted use has been associated with irritant contact dermatitis and, uncommonly and mainly with high concentrations or very extended use, exogenous ochronosis — a paradoxical blue-grey discolouration that is difficult to treat. For this reason, physicians typically prescribe it in defined courses with planned breaks rather than indefinitely. Regulatory status differs by country: availability over the counter, by prescription only, or restricted varies, and patients should follow the rules and physician guidance in their own jurisdiction.

How Tranexamic Acid Works

Tranexamic acid is an antifibrinolytic agent — originally used to reduce bleeding — that has been repurposed for melasma. The proposed mechanism is inhibition of plasminogen activation in keratinocytes, reducing downstream arachidonic acid and prostaglandin signalling that stimulates melanocytes, with an additional effect on the increased dermal vascularity seen in melasma.

It is used topically, intradermally by microinjection, and orally. The oral route has attracted the most research interest because several trials and meta-analyses report meaningful improvement in melasma severity scores, but it is also the route with systemic considerations. Oral tranexamic acid is generally contraindicated or requires careful specialist assessment in people with a personal or family history of thromboembolism, certain clotting disorders, active cancer, or concurrent use of hormonal contraception, among other factors. Screening before prescription is not optional, dosing is a physician decision, and self-medication with oral tranexamic acid is unsafe.

Head to Head: What the Evidence Does and Does Not Show

This is where most consumer comparisons overreach. Randomised comparisons of topical tranexamic acid against hydroquinone have frequently reported broadly comparable improvement in melasma severity scores, with some studies reporting fewer irritation-related side effects in the tranexamic acid arms. However, many of these trials are small, run for relatively short periods — commonly 8 to 12 weeks — and use varied concentrations and vehicles, which limits how confidently the findings can be generalised.

What can be said with more confidence: neither agent produces durable results without rigorous photoprotection; relapse after stopping is common with both; and combination regimens are widely used in practice precisely because single-agent monotherapy frequently plateaus. Claims that either agent "clears" melasma permanently are not supported by the current literature.

How These Fit Into Korean Dermatology Practice

Korean clinics commonly treat melasma as a long-horizon maintenance problem rather than a course of treatment. A typical approach layers strict daily broad-spectrum photoprotection, a topical regimen, and conservative energy-based treatment where appropriate — with device settings chosen cautiously because aggressive laser treatment can worsen melasma through post-inflammatory hyperpigmentation, particularly in higher Fitzpatrick skin types. Understanding your own Fitzpatrick skin type and its implications for laser safety is directly relevant before agreeing to any device-based plan.

For international patients this creates a practical constraint: melasma management is not well suited to a single short trip. A realistic plan usually includes a treatment initiated in Korea and a maintenance regimen continued at home under local medical supervision, with prescriptions that are legally obtainable in your own country.

Photoprotection: The Non-Negotiable Variable

Both agents are generally reported to underperform without consistent sun protection. Beyond conventional UV filters, visible light — particularly in the blue range — has been implicated in pigment darkening in melasma-prone skin, which is why tinted or iron-oxide-containing sunscreens are frequently recommended. Reapplication discipline and physical measures such as hats and shade are part of the regimen rather than optional additions. A patient who will not maintain photoprotection is unlikely to sustain results from either agent.

Practical Questions to Ask Your Physician

1. Is my diagnosis confirmed as melasma rather than post-inflammatory hyperpigmentation or another pigmentary condition? 2. If hydroquinone is proposed, for how many weeks, and what is the planned break and monitoring schedule? 3. If oral tranexamic acid is proposed, what screening for thrombotic risk will be done, and what should prompt me to stop? 4. What is the maintenance plan after the initial course, and can I obtain it legally at home? 5. What is the realistic expected improvement, and over what timeframe?

Frequently Asked Questions

Is tranexamic acid safer than hydroquinone?

They carry different risks rather than sitting on a single safety scale. Topical hydroquinone risks are mainly local; oral tranexamic acid introduces systemic considerations requiring medical screening. Neither is categorically safer for every patient.

Can they be used together?

Combination regimens are used in practice and studied in the literature, but combining agents should be a physician decision based on your skin type, diagnosis, and history rather than self-assembled.

How long until results appear?

Studies commonly assess outcomes at 8 to 12 weeks, and clinical improvement is typically gradual rather than sudden. Expectations of rapid clearance are generally unrealistic.

Will melasma come back if I stop?

Recurrence after discontinuation is commonly reported with both agents, particularly without sustained photoprotection. Most physicians frame melasma as managed rather than cured.

Are over-the-counter "tranexamic acid" serums equivalent to a prescription?

Not necessarily. Cosmetic formulations vary widely in concentration, derivative form, and vehicle, and are not equivalent to studied prescription preparations. Read the actual ingredient list and discuss with a physician.

Related Reading

How Pico Laser Actually Works: The Mechanism Explained · Understanding Fitzpatrick Skin Types for Laser Safety · Retinol vs Tretinoin vs Adapalene: A Complete Prescription Guide

Sources and Further Reading

Korea Health Industry Development Institute (KHIDI) · Korean Medical Association (KMA) · PubMed — tranexamic acid versus hydroquinone in melasma

Before You Start Either Treatment

If you are weighing tranexamic acid vs hydroquinone for melasma, the decision belongs with a dermatologist who has examined your skin and reviewed your medical history — particularly before any oral therapy. This article is general information and is not medical advice or a treatment recommendation.